Objective: TheMEMD gene was reported to be overexpressed in human esophageal squamous cell carcinoma (ESCC), using differential display. The aim of this study was to determine the clinical significance of MEMD/ALCAM in esophageal tumorigenesis. Methods: Analysis of MEMD/ALCAM expression in esophageal tissues was carried out at protein and RNA level using immunohistochemistry and semiquantitative RT-PCR, respectively. Results: Increased MEMD/ALCAM expression was observed in 42/65 (65%) ESCCs (p = 0.000, odds ratio, OR = 3.665) and in 17/25 (68%) dysplasias (p = 0.000, OR = 4.248) compared to paired distant histologically normal esophageal tissues. Increased MEMD mRNAlevels were observed in ESCCs and dysplasias showing overexpression of MEMD/ALCAM protein. Interestingly, increased membranous MEMD/ALCAM expression was observed in dysplasias in comparison with ESCCs (p = 0.002, OR = 3.177). MEMD/ALCAM overexpression in ESCCs was associated with late clinical stage (p = 0.002, OR = 3.619), enhanced tumor invasiveness (p = 0.002, OR = 3.619), and nodal metastasis (p = 0.000, OR = 4.206). Conclusion: To our knowledge, this is the first report showing MEMD expression at pre-malignant stage (dysplasia), suggesting that MEMD/ALCAM expression is an early event in the development of esophageal cancer. Furthermore, in ESCCs its correlation with late clinical stage, enhanced tumor invasiveness and nodal metastasis suggests an association with aggressive tumor behavior. Our data suggest that MEMD/ALCAM may serve as a potential marker for early diagnosis, tumor invasion and nodal metastasis in ESCCs.

Keywords:
Dysplasia, Esophageal squamous cell carcinoma, Immunohistochemistry, MEMD/ALCAM, RT-PCR, Squamous cell carcinoma
1.
Kohn EC, Liotta LA: Molecular insights into cancer invasion: Strategies for prevention and intervention. Cancer Res 1995;55:1856–1862.
2.
Degen WGJ, van Kempen LCLT, Gijzen EGA, van Groningen JJM, van Kooyk Y, Bloemers HPJ, Swart GWM: MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol 1998;152:805–813.
3.
Pourquie O, Corbel C, Le Caer JP, Rossier J, Le Douarin NM: BEN, a surface glycoprotein of the immunoglobulin superfamily, is expressed in a variety of developing systems. Proc Natl Acad Sci USA 1992;89:5261–5265.
4.
Burns FR, von Kannen S, Guy L, Raper JA, Kamholz J, Chang S: DM-GRASP, a novel immunoglobulin superfamily axonal surface protein that supports neurite extension. Neuron 1991;7:209–220.
5.
Tanaka H, Matsui T, Agata A, Tomura M, Kubota I, McFarland KC, Kohr B, Lee A, Phillips HS, Shelton DL: Molecular cloning and expression of a novel adhesion molecule, SC1. Neuron 1991;7:535–545.
6.
Lehmann JM, Riethmuller G, Johnson JP: MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 1989;86:9891–9895.
7.
Matsumoto A, Mitchell A, Kurata H, Pyle L, Kondo K, Itakura H, Fidge N: Cloning and characterization of HB2, a candidate high density lipoprotein receptor. Sequence homology with members of the immunoglobulin superfamily of membrane proteins. J Biol Chem 1997;272:16778–16782.
8.
Uchida N, Yang Z, Combs J, Pourquie O, Nguyen M, Ramanathan R, Fu J, Welply A, Chen S, Weddell G, Sharma AK, Leiby KR, Karagogeos D, et al: The characterization, molecular cloning, and expression of a novel hematopoietic cell antigen from CD34+ human bone marrow cells. Blood 1997;89:2706–2716.
9.
Cortes F, Deschaseaux F, Uchida N, Labastie MC, Friera AM, He D, Charbord P, Peault B: HCA, an immunoglobulin-like adhesion molecule present on the earliest human hematopoietic precursor cells, is also expressed by stromal cells in blood-forming tissues. Blood 1999;93:826–837.
10.
Patel DD, Wee SF, Whichard LP, Bowen MA, Pesando JM, Aruffo A, Haynes BF: Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells. J Exp Med 1995;181:1563–1568.
11.
Levesque MC, Heinly CS, Whichard LP, Patel DD: Cytokine-regulated expression of activated leukocyte cell adhesion molecule (CD166) on monocyte-lineage cells and in rheumatoid arthritis synovium. Arthritis Rheum 1998;41:2221–2229.
12.
Sekine-Aizawa Y, Omori A, Fujita SC: MuSC, a novel member of the immunoglobulin superfamily, is expressed in neurons of a subset of cranial sensory ganglia in the mouse embryo. Eur J Neurosci 1998;10:2810–2824.
13.
Heffron DS, Golden JA: DM-GRASP is necessary for nonradial cell migration during chick diencephalic development. J Neurosci 2000;20:2287–2294.
14.
Bruder SP, Ricalton NS, Boynton RE, Connolly TJ, Jaiswal N, Zaia J, Barry FP: Mesenchymal stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation. J Bone Miner Res 1998;13:655–663.
15.
Bowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang WC, Marquardt H, Neubauer M, Pesando JM, Francke U, Haynes BF, Aruffo A: Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 1995;181:2213–2220.
16.
Bodian DL, Skonier JE, Bowen MA, Neubauer M, Siadak AW, Aruffo A, Bajorath J: Identification of residues in CD6 which are critical for ligand binding. Biochemistry 1997;36:2637–2641.
17.
Bowen MA, Bajorath J, D’Egidio M, Whitney GS, Palmer D, Kobarg J, Starling GC, Siadak AW, Aruffo A: Characterization of mouse ALCAM (CD166): The CD6-binding domain is conserved in different homologs and mediates cross-species binding. Eur J Immunol 1997;27:1469–1478.
18.
Skonier JE, Bodian DL, Emswiler J, Bowen MA, Aruffo A, Bajorath J: Mutational analysis of the CD6 ligand binding domain. Protein Eng 1997;10:943–947.
19.
Van Kempen LCLT, Van den Oord J, Van Muijen G, Weidle UH, Bloemers HPJ, Swart GWM: Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 2000;156:769–774.
20.
Tomita K, van Bokhoven A, Jansen CF, Bussemakers MJ, Schalken JA: Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin. Biochem Biophys Res Commun 2000;267:870–874.
21.
Nelissen JM, Peters IM, De Grooth BG, Van Kooyk Y, Figdor CG: Dynamic regulation of activated leukocyte cell adhesion molecule-mediated homotypic cell adhesion through the actin cytoskeleton. Mol Biol Cell 2000;11:2057–2068.
22.
Feizi T: Evidence for carbohydrate-mediated interactions between the neural-cell-adhesion molecules NCAM and L1. Trends Biochem Sci 1994;19:233–234.
23.
Silletti S, Mei F, Sheppard D, Montgomery AM: Plasmin-sensitive dibasic sequences in the third fibronectin-like domain of L1-cell adhesion molecule (CAM) facilitate homomultimerization and concomitant integrin recruitment. J Cell Biol 2000;149:1485–1502.
24.
Sharma R, Samantaray S, Shukla NK, Ralhan R: Transcriptional gene expression profile of human esophageal squamous cell carcinoma. Genomics 2003;81: 481–488.
25.
Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:1803–1804.
26.
AJCC Cancer Staging Manual, ed 5. Philadelphia, Lippincott-Raven, 1997.
27.
Chakravarti N, Mathur M, Bahadur S, Shukla NK, Ralhan R: Retinoic acid receptor-alpha as a prognostic indicator in oral squamous cell carcinoma. Int J Cancer 2003;103:544–549.
28.
Zheng X, Ding W, Xie L, Chen Z: Expression and significance of activated leukocyte cell adhesion molecule in prostatic intraepithelial neoplasia and adenocarcinoma (in Chinese). Zhonghua Nan Ke Xue 2004;10:265–268.
29.
Kristiansen G, Pilarsky C, Wissmann C, Stephen C, Weissbach L, Loy V, Loening S, Dietel M, Rosenthal A: ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 2003;54:34–43.
30.
Choi S, Kobayashi M, Wang J, Habelhah H, Okada F, Hamada J, Moriuchi T, Totsuka Y, Hosokawa M: Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with Adriamycin. Clin Exp Metastasis 2000;18:45–50.
31.
Van Kempen LC, Meier F, Egeblad M, Kersten-Niessen MJ, Garbe C, Weidle UH, Van Muijen GN, Herlyn M, Bloemers HP, Swart G: Truncation of activated leukocyte cell adhesion molecule: A gateway to melanoma metastasis. J Invest Dermatol 2004;122:1293–1301.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.